Prevention of arterial thrombosis (arteriothromboprophylaxis) in clinical practice
Authors:
P. Gavornik
Authors‘ workplace:
Vedúci lekár: doc. MUDr. Peter Gavorník, PhD., mim. prof.
; Prednosta: prof. MUDr. Andrej Dukát, CSc., FESC.
; Prvé angiologické pracovisko (PAP)
; II. interná klinika LFUK – FNsP, Bratislava
Published in:
Prakt. Lék. 2009; 89(7): 395-398
Category:
Therapy
Overview
Anti-platelet therapy with acetylsalicylic acid (aspirin) has provided pivotal advances in the prevention and treatment of obliterating (coronary; cerebral, extremities, renal, genital, ocular and other peripheral) arterial cardio-vascular diseases. Currently available anti-platelet drugs have some limitations which may be overcome by improved dosage regimes, the use of a combination of agents affecting different platelet functions and, in particular, by the new anti-platelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including quicker onset of action, greater potency, and reversibility of effects.
Key words:
arterial vascular system, arterial thrombosis, arteriothromboprophylaxis, classical antiplatelet drugs, new arterial antithrombotics.
Sources
1. Antithrombotic and thrombolytic therapy: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines (8th edition). Chest 2008, 133, (6 Suppl), 67S-968S.
2. Bates, S.M., Weitz, J.I. New antitrombotic drugs. In: Coman RW, Marder VJ, Clowes AW (Eds). Hemostasis and Thrombosis. Basic principles of clinical practice. 5th ed. Philadelphia: Lippincott Williams and Wilkins 2006, p. 1763-1783.
3. Bátorová, A. Protidoštičkové lieky – súčasnosť a nové perpektívy. Kardiol. prax. 2008, 6 (2), s. 79-86
4. Gachet, C., Aleil, B. Testing antiplatelet therapy. Eur. Heart J. 2008; 10 (Suppl), p. 28-34.
5. Gavorník, P. Prevencia vénovej trombózy (flebotromboprofylaxia) v klinickej praxi. Prakt. lék. 2009, 89: v tisku.
6. Gavorník, P. Vaskulárna endotelová dysfunkcia – etiopatogenéza, základné diagnostické metódy a liečebné možnosti. Gen. angiol. 2002; 2(2), s. 59-66.
7. Gavorník, P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. 2. vyd. Univerzita Komenského – Vydavateľstvo UK. Bratislava: 2001. 268. ISBN 80-223-1608-3.
8. Hricák, V. Aktualizované odporúčania pre používanie klopidogrelu u pacientov s akútnym koronárnym syndrómom, stabilnou angínou pektoris a pri sekundárnej prevencii aterotrombotických príhod. Cardiol. 2009, 18 (2), s. 87-90.
9. Hudec, R. Prasugrel (Efient). Interná med. 2009, 9 (Suppl 1), S44-S45.
10. Husted, S. New developments in oral antiplatelet therapy. Eur. Heart J, 2007, 9 (Suppl), D20-D27.
11. Kriška, M. Rajec, J. Aspirínová dilema. Interná med. 2008, 8 (6), s. 361-364.
12. Leger, A.J., Covic, L., Kuliopulos, A. Protease-actived receptors in cardiovascular diseases. Circulation 2006, 114, p. 1070-1077.
13. Michelson, A.D. (ed). Platelets. 2nd ed. San Diego: Elsevier/Academic Press, 2007.
14. Morrow, D.A., Wiviott, S.D., White, H.D. et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction: An application of the classification system from the universal definition of myocardial infarction. Circulation 2009, 119 (21), p. 2758-2764.
15. Pecka, M., Malý, J. Metabolické a aktivačné děje v krevních deštičkách a možnosti jejich inhibice. Vnitř. Lék. 2009, 55 (3), s. 263-266.
16. Remková, A. Aktuálne otázky antidoštičkovej liečby kyselinou acetylsalicylovou v primárnej a sekundárnej prevencii cievnych ochorení u diabetikov. Interná med. 2007, 7 (1), p. 36-39.
17. Sorbera, L.A., Serradell, N., Bolós, J. et al. Terutroban sodium. Drugs Fut. 2006, 31, p. 867.
18. The seventh American College of Chest Physicians (ACCP) conference on antithrombotic and thrombolytic therapy. From evidence to application. Chest 2004, 126 (3 Suppl), 1S-696S.
19. Uhrinová, A., Pišková, T. Klinický význam a liečba hyperurikémie pri cievnych chorobách a cievnych poruchách. Prakt. flebol. 2007, 16 (2), s. 45-48.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2009 Issue 7
Most read in this issue
- Regional migratory osteoporosis – a differential diagnostic problem
- Professional misconduct and errors in medical practice
- Treatment of cannabis dependence
- Prevention of arterial thrombosis (arteriothromboprophylaxis) in clinical practice